Xolair® CRSwNP - initial reimbursement request annex A (Dutch)
Download Dutch document
.field-name-field-np4-expiry-date {display:none;}
To receive by post, click on the "Add to card" button below
Xolair® CRSwNP - initial reimbursement request annex B (Dutch)
Download Dutch document .field-name-field-np4-expiry-date {display:none;} To receive by post, click on the "Add to card" button belowXolair® CRSwNP - reimbursement extension annex C (Dutch)
Download Dutch document .field-name-field-np4-expiry-date {display:none;} To receive by post, click on the "Add to card" button belowXolair® CRSwNP - initial reimbursement request annex A (French)
Download French document .field-name-field-np4-expiry-date {display:none;} To receive by post, click on the "Add to card" button belowXolair® CRSwNP - initial reimbursement request annex B (French)
Download French document .field-name-field-np4-expiry-date {display:none;} To receive by post, click on the "Add to card" button belowXolair® CRSwNP - reimbursement extension annex C (French)
Download French document .field-name-field-np4-expiry-date {display:none;} To receive by post, click on the "Add to card" button belowReimbursement / eHealth
Xolair® SAA - initial reimbursement request annex A (French)
Download French document .field-name-field-np4-expiry-date {display:none;} To receive by post, click on the "Add to card" button belowReimbursement
Indication
FABHALTA ® is indicated as monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who have haemolytic anemia 1 .
FABHALTA® is the first and only Factor B inhibitor. FABHALTA® acts...
Twitter Linkedin Facebook Pinterest Google plus